Ziv-aflibercept (Zaltrap) for the Treatment of Metastatic Colorectal Cancer

Perkins, Scott; Cole, Sabrina

doi:10.1177/1060028013506562

Cited by 17 publications

(8 citation statements)

References 18 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastasized colorectal cancer [116] Abbreviations: VEGF: vascular endothelial growth factor; VEGFR: Vascular endothelial growth fac tor receptor; FKBP-12: FK Binding Protein-12; mTOR: mammalian target of Rapamycin; IgG1: im munoglobulin gamma 1.…”

Section: Vegf Inhibitormentioning

confidence: 99%

The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview

et al. 2022

View full text Add to dashboard Cite

Angiogenesis is the process of developing new blood vessels from pre-existing ones. This review summarizes the main features of physiological and pathological angiogenesis and those of angiogenesis activation and inhibition. In healthy adults, angiogenesis is absent apart from its involvement in female reproductive functions and tissue regeneration. Angiogenesis is a complex process regulated by the action of specific activators and inhibitors. In certain diseases, modulating the angiogenic balance can be a therapeutic route, either by inhibiting angiogenesis (for example in the case of tumor angiogenesis), or by trying to activate the process of new blood vessels formation, which is the goal in case of cardiac or peripheral ischemia.

show abstract

Section: Vegf Inhibitormentioning

confidence: 99%

The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It was also approved in a combination treatment for colorectal cancer in 2012 (ReF. 41 ), for treatment of diabetic macular oedema and macular oedema following retinal vein occlusion in 2014 and for treatment of diabetic retinopathy in 2015.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Soluble ligands as drug targets

Attwood

Jönsson

Rask‐Andersen

et al. 2020

Nat Rev Drug Discov

View full text Add to dashboard Cite

show abstract

“…Zaltrap (ziv‐aflibercept) is constructed from the extracellular domains of human vascular endothelial growth factor (VEGF) receptors 1 and 2 that are fused to the Fc domain of IgG (Salem & El‐Refai, ). Zaltrap is used as a chemotherapeutic in treating metastatic colorectal cancer (Perkins & Cole, ; “Zaltrap, ”). Therapeutic activity is based on blood vessel growth inhibition from the VEGF receptor portion of the fusion protein; the Fc‐domain mainly functions to increase half‐life through FcRn binding.…”

Section: Antibody Conjugates and Fusionsmentioning

confidence: 99%

Antibody and antibody derivatives as cancer therapeutics

Arlotta

Owen

2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Antibodies are an important class of therapeutic for treating a wide range of diseases. These versatile macromolecules can be engineered to target many different antigens and to utilize several mechanisms of action to produce a pharmacological effect. The most common antibody platform used for therapeutics is immunoglobulin G (IgG). Advances in protein-display and genetic engineering have enabled the construction and manipulation of IgG to enhance desired activity such as increasing antigen affinity, modulating pharmacokinetics, and enhancing effector functions.IgGs can also be altered to suppress undesired effects, such as immunogenicity. The main approaches to control IgG behavior include engineering the protein sequence and glycosylation of intact IgG; constructing IgG-based derivatives, including bispecific and multivalent binders; and fusing small-drug molecules or proteins to IgG-derived scaffolds. Often, a single modification applied to a given IgG can alter more than one property. The desired effects of an antibody therapeutic should be carefully tailored to the physiology and characteristics of each disease condition.

show abstract

Ziv-aflibercept (Zaltrap) for the Treatment of Metastatic Colorectal Cancer

Abstract: Ziv-aflibercept is a safe and effective option in combination with FOLFIRI for the treatment of mCRC in patients who progress on oxaliplatin-containing therapy. Superiority over other antiangiogenic treatment has not been established.

Cited by 17 publications

References 18 publications

The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview

The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview

Soluble ligands as drug targets

Antibody and antibody derivatives as cancer therapeutics

Contact Info

Product

Resources

About